Last reviewed 2026-04-22 · How we verify

GRASS 2800 BAU

Clinique Spécialisée en Allergies de la Capitale · FDA-approved active Small molecule

GRASS 2800 BAU is a Allergen immunotherapy extract Small molecule drug developed by Clinique Spécialisée en Allergies de la Capitale. It is currently FDA-approved for Allergic rhinitis and/or allergic asthma caused by grass pollen. Also known as: GRASTEK.

GRASS 2800 BAU is a grass pollen allergen extract that desensitizes the immune system to grass pollen through repeated exposure, reducing allergic responses.

GRASS 2800 BAU is a grass pollen allergen extract that desensitizes the immune system to grass pollen through repeated exposure, reducing allergic responses. Used for Allergic rhinitis and/or allergic asthma caused by grass pollen.

At a glance

Generic name	GRASS 2800 BAU
Also known as	GRASTEK
Sponsor	Clinique Spécialisée en Allergies de la Capitale
Drug class	Allergen immunotherapy extract
Target	Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species)
Modality	Small molecule
Therapeutic area	Immunology / Allergy
Phase	FDA-approved

Mechanism of action

This is an allergen immunotherapy (AIT) product containing standardized grass pollen allergens measured in Biological Activity Units (BAU). It works by gradually inducing immune tolerance to grass pollen antigens, shifting the immune response from IgE-mediated (allergic) to IgG-mediated (protective) antibodies and promoting regulatory T cells. With repeated administration, patients develop reduced sensitivity to natural grass pollen exposure.

Approved indications

Allergic rhinitis and/or allergic asthma caused by grass pollen

Common side effects

Local reactions at injection site (itching, swelling, erythema)
Oral pruritus
Systemic allergic reactions
Anaphylaxis

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRASS 2800 BAU CI brief — competitive landscape report
GRASS 2800 BAU updates RSS · CI watch RSS
Clinique Spécialisée en Allergies de la Capitale portfolio CI

Frequently asked questions about GRASS 2800 BAU

What is GRASS 2800 BAU?

GRASS 2800 BAU is a Allergen immunotherapy extract drug developed by Clinique Spécialisée en Allergies de la Capitale, indicated for Allergic rhinitis and/or allergic asthma caused by grass pollen.

How does GRASS 2800 BAU work?

GRASS 2800 BAU is a grass pollen allergen extract that desensitizes the immune system to grass pollen through repeated exposure, reducing allergic responses.

What is GRASS 2800 BAU used for?

GRASS 2800 BAU is indicated for Allergic rhinitis and/or allergic asthma caused by grass pollen.

Who makes GRASS 2800 BAU?

GRASS 2800 BAU is developed and marketed by Clinique Spécialisée en Allergies de la Capitale (see full Clinique Spécialisée en Allergies de la Capitale pipeline at /company/clinique-sp-cialis-e-en-allergies-de-la-capitale).

Is GRASS 2800 BAU also known as anything else?

GRASS 2800 BAU is also known as GRASTEK.

What drug class is GRASS 2800 BAU in?

GRASS 2800 BAU belongs to the Allergen immunotherapy extract class. See all Allergen immunotherapy extract drugs at /class/allergen-immunotherapy-extract.

What development phase is GRASS 2800 BAU in?

GRASS 2800 BAU is FDA-approved (marketed).

What are the side effects of GRASS 2800 BAU?

Common side effects of GRASS 2800 BAU include Local reactions at injection site (itching, swelling, erythema), Oral pruritus, Systemic allergic reactions, Anaphylaxis.

What does GRASS 2800 BAU target?

GRASS 2800 BAU targets Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species) and is a Allergen immunotherapy extract.

Drug class: All Allergen immunotherapy extract drugs
Target: All drugs targeting Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species)
Manufacturer: Clinique Spécialisée en Allergies de la Capitale — full pipeline
Therapeutic area: All drugs in Immunology / Allergy
Indication: Drugs for Allergic rhinitis and/or allergic asthma caused by grass pollen
Also known as: GRASTEK

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing